INVESTABOT
Equity Research
XNAS · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Gilead Sciences (GILD) had 1 Form 144 pre-sale notice filed on 2026-08-03. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Gilead Sciences (GILD) had 2 Form 144 pre-sale notices filed on 2026-07-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fi…
Gilead Sciences (GILD) had 2 Form 144 pre-sale notices filed on 2026-06-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fi…
Gilead Sciences (GILD) had 1 Form 144 pre-sale notice filed on 2026-06-01. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fil…
Gilead Sciences (GILD) had 2 Form 144 pre-sale notices filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one fi…
TL;DR: Gilead Sciences reported Q1 2026 EPS of $1.61, up 54.8% from $1.04 a year ago, on total revenues of $7.0 billion. The company immediately raised its full-year revenue guidance, signaling management's confidence th…
Gilead Sciences (GILD) had 3 Form 144 pre-sale notices filed between 2026-04-15 and 2026-04-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transact…
Gilead Sciences Inc (GILD) had 3 Form 144 pre-sale notices filed between 2026-04-15 and 2026-04-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed tran…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 8/10/2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | OPTION_EXERCISE | -6,002 | — | — |
| 8/10/2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | TAX_WITHHOLD | -2,908 | $133 | $386,938 |
| 8/10/2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | OPTION_EXERCISE | 6,002 | — | — |
| 8/3/2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | -6,700 | $130 | $868,711 |
| 8/3/2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | -7,700 | $131 | $1,007,177 |
| 8/3/2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | -600 | $131 | $78,806 |
| 7/15/2026 | Dickinson Andrew D | Chief Financial Officer | SELL | -3,000 | $130 | $389,777 |
| 7/15/2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | -3,000 | $130 | $389,758 |
| 7/1/2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | -11,900 | $126 | $1,500,467 |
| 7/1/2026 | O'Day Daniel Patrick | Chairman & CEO | SELL | -3,100 | $127 | $393,933 |
| 6/15/2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | -1,480 | $123 | $182,657 |
| 6/15/2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | -1,070 | $124 | $132,676 |
| 6/15/2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | -450 | $125 | $56,430 |
| 6/15/2026 | Dickinson Andrew D | Chief Financial Officer | SELL | -3,000 | $125 | $376,200 |
| 6/10/2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | OPTION_EXERCISE | 589 | — | — |
| 6/10/2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | TAX_WITHHOLD | -283 | $121 | $34,379 |
| 6/10/2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | OPTION_EXERCISE | -589 | — | — |
| 6/10/2026 | Berger Dietmar | Chief Medical Officer | OPTION_EXERCISE | 533 | — | — |
| 6/10/2026 | Berger Dietmar | Chief Medical Officer | TAX_WITHHOLD | -263 | $121 | $31,949 |
| 6/10/2026 | Berger Dietmar | Chief Medical Officer | OPTION_EXERCISE | -533 | — | — |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| 8/3/2026 | DANIEL O'DAY | — | 55,000 | SEC |
| 7/15/2026 | JOHANNA MERCIER | — | 3,000 | SEC |
| 7/15/2026 | ANDREW DICKINSON | — | 3,000 | SEC |
| 6/15/2026 | ANDREW DICKINSON | — | 3,000 | SEC |
| 6/15/2026 | JOHANNA MERCIER | — | 3,000 | SEC |
| 6/1/2026 | DANIEL O'DAY | — | 35,000 | SEC |
| 5/15/2026 | ANDREW DICKINSON | — | 3,000 | SEC |
| 5/15/2026 | JOHANNA MERCIER | — | 28,000 | SEC |
| 4/28/2026 | DANIEL O'DAY | — | — | SEC |
| 4/15/2026 | JOHANNA MERCIER | — | 3,000 | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 119,010,973 | $16,586,559,275 | -3.4% | 5/13/2026 |
| BlackRock | 121,844,108 | $15,393,784,619 | 2.4% | 8/7/2026 |
| BlackRock | 123,195,578 | $15,121,025,249 | — | 2/12/2026 |
| Vanguard Group | 121,097,336 | $14,863,487,020 | — | 1/29/2026 |
| Fidelity (FMR) | 71,906,290 | $10,021,579,771 | 9.7% | 5/15/2026 |
| Fidelity (FMR) | 66,870,816 | $8,448,459,045 | -7.0% | 8/13/2026 |
| State Street | 59,858,585 | $8,342,490,991 | -0.6% | 5/15/2026 |
| BlackRock | 120,632,023 | $8,276,563,065 | — | 8/13/2024 |
| Fidelity (FMR) | 65,579,490 | $8,049,226,574 | — | 2/17/2026 |
| State Street | 61,216,552 | $7,734,099,180 | 2.3% | 8/7/2026 |
| State Street | 60,240,518 | $7,393,921,179 | — | 2/13/2026 |
| JP Morgan Chase | 34,371,910 | $4,686,266,476 | 44.0% | 5/13/2026 |
| Morgan Stanley | 23,299,295 | $3,247,223,306 | -0.9% | 5/15/2026 |
| Morgan Stanley | 24,004,354 | $3,032,710,535 | 3.0% | 8/13/2026 |
| JP Morgan Chase | 23,871,863 | $2,930,032,699 | — | 2/11/2026 |
| Morgan Stanley | 23,512,734 | $2,885,953,592 | — | 5/27/2026 |
| JP Morgan Chase | 21,353,121 | $2,697,539,871 | -37.9% | 8/12/2026 |
| Goldman Sachs | 11,542,014 | $1,608,610,528 | 30.9% | 5/15/2026 |
| Goldman Sachs | 11,199,994 | $1,415,007,373 | -3.0% | 8/14/2026 |
| Goldman Sachs | 8,814,813 | $1,081,930,201 | — | 3/25/2026 |